Clin Cancer Res 2020 Jan 1
Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer.
Related Questions
In which situations would you consider this a reasonable treatment option?
New answer by Medical Oncologist at Mayo Clinic (October 6, 2021)
Whereas ER 1-9% represents a heterogeneous group of tumors with relatively poor response to endocrine monotherapy, there are few if any data on whether this group of patients ...